Signe Erickson

Signe Erickson has a diverse work experience spanning several industries and roles. Most recently, they served as the Chief Operating Officer at Myra Vision starting in April 2023. Prior to that, from 2019 to 2023, Signe was the Chief Scientific Officer at Spiral Therapeutics. Before joining Spiral Therapeutics, they worked at Genentech, first as the Senior Medical Science Director from February 2018 to November 2018, and then as the Director of Device Development and ForSight VISION4 Site Lead from March 2017 to February 2018. From 2009 to 2017, Signe held various positions at ForSight VISION4, including Senior Vice President of Product Development and Vice President of Development and Clinical Application. Earlier in their career, they worked as the Director of Ophthalmology R&D at SurModics from 2005 to 2009, and as an Assistant Professor at USC, Doheny Eye Institute from 2001 to 2004. Signe also gained research experience as a Research Fellow at Johns Hopkins, Wilmer Eye Institute from 2000 to 2001 and as a Scientist at AtheroGenics from 1998 to 2000.

Signe Erickson received a Bachelor of Science degree in Mechanical Engineering from Auburn University, from 1987 to 1991. Following that, they pursued a PhD in Bioengineering at the Georgia Institute of Technology, completing the program from 1991 to 1997.